Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.
Sera Prognostics reported Q3 2026 financial results, highlighting a 54% sequential increase in PreTRM test volume and a five-fold increase since Q1 2026. The company secured Medicaid coverage for its test in Florida, following a similar win in Illinois, and ended the quarter with $72.8 million in cash and marketable securities.
Term
Q3 2026
“The third quarter marked an important step forward as we continued our transition from evidence generation to commercial execution. We delivered strong growth in physician adoption and test volume, saw expanded reimbursement through a second state Medicaid coverage win in Florida, advanced our commercial payer initiatives, and continued to strengthen our clinical and health economic evidence base.”
Zhenya Lindgardt, President and Chief Executive Officer
Pacific Biosciences of California Financial Results
Pacific Biosciences reported Q3 2026 revenue of $40.6 million, driven by demand for its Revio and Vega sequencing systems. Alongside the results, the company announced that CFO Jim Gibson has stepped down and transitioned to an advisory role, with CEO Mark Van Oene serving as interim CFO during a search for a permanent successor.
Term
Q3 2026
“PacBio is entering an exciting phase as the investments we’ve made in our technology begin to unlock new opportunities. SPRQ-Nx is changing the economics of HiFi sequencing, while growing clinical adoption and strategic collaborations in population genomics and AI are expanding the markets we can serve. We have a tremendous opportunity ahead of us, and my focus is clear: sharpen our execution, prioritize what matters most, and translate the strength of our technology into sustainable growth.”
Mark Van Oene, President and Chief Executive Officer
Arcus Biosciences reported total revenues of $67 million for the nine months ended September 30, 2026, a significant decrease from $214 million in the prior year period, primarily due to lower license and development services revenue. The company recorded a net loss of $347 million for the first nine months of 2026, compared to a net loss of $247 million in 2025, as operating expenses continued to outpace revenue.
Silvaco Group reported third quarter 2026 financial results with revenue of $16.3 million and a GAAP net loss of $4.6 million. The company highlighted record bookings in its TCAD segment and issued strong Q4 guidance, expecting 35% sequential revenue growth driven by new Tier-1 customer wins.
Term
Q3 2026
“I am pleased with Silvaco’s Q3 results and Q4 guidance. In Q3, bookings strength was driven by a significant new Tier-1 FTCO customer and 4 tier-1 customer wins for Jivaro Pro. We also engaged with two of the largest global technology companies with our Agentic AI offerings. Looking forward, we expect strong revenue growth, with 35% sequential growth expected in Q4, 17% growth year-over-year in 2026 and mid-to-high teens growth in 2027.”
Walden Rhines, Silvaco’s Chief Executive Officer
“As the business accelerates, we are achieving meaningful financial milestones. Net cash used in operations improved significantly in Q3, we ended Q3 with the most unrestricted cash on the balance sheet since Q2’25 and we are guiding to record revenue in Q4. We expect our higher growth expectations to continue expanding our profitability and cash generation in 2027.”
Chris Zegarelli, Silvaco’s Chief Financial Officer
Meta Platforms Director Marc L. Andreessen Sells $12.8M of Stock
Marc L. Andreessen, Director, sold 20,951 shares of Meta Platforms, Inc. at $606.85 to $613.88 a share (average $609.74) in 8 transactions, worth $12.8M in total on Nov 2, 2026. Shares held after the trade: 0 (-100.0%).
Sunrun reported Q3 2026 financial results, highlighting a record 75% storage attachment rate and a return to growth in its direct installation business. The company generated $56 million in cash (excluding safe harbor investments) and revised its full-year 2026 cash generation guidance to approximately $200 million.
Term
Q3 2026
“Sunrun has returned its direct business to growth, with installations increasing 9% year-over-year. Sunrun is the nation's largest Residential Independent Power Producer. We hit a 75% attachment rate of storage assets, the highest in our history. The need for affordable, reliable power has never been more evident, and our storage-first offering is meeting it. We are positioning the business for strong growth, bringing on some of the best talent in the industry and scaling deliberately, with a focus on customer experience and asset quality. And as that engine scales, we're aiming to unlock new ways to monetize the network we've already built, from distributed power plant programs to emerging data center and grid edge applications, creating new streams of Cash Generation.”
Mary Powell, Sunrun’s Chief Executive Officer
“Q3 marked an important inflection point as we returned to growth in our direct business and expanded our Upfront Net Subscriber Value margins considerably. We delivered $56 million in Cash Generation in Q3, excluding investments in equipment for safe harbor activities, and expect higher Cash Generation in Q4 resulting in full-year Cash Generation of approximately $200 million.”
Chime Financial reported third-quarter 2026 revenue of $718 million, a 32% year-over-year increase, and achieved its third consecutive quarter of GAAP profitability with net income of $44 million. The company added 1.8 million net new Active Members over the past year, bringing the total to 10.9 million, driven by growth in its Chime Prime and lending businesses. Based on strong momentum in MyPay and Instant Loans, Chime raised its full-year 2026 financial outlook.
Term
Q3 2026
“This was our strongest quarter yet as a public company, and we are seeing structural improvements in our growth and profitability profile. We added a record 1.8 million net new Active Members over the past year, accelerated revenue growth to 32%, and delivered our third consecutive quarter of GAAP profitability. Chime Prime and our growing lending business are deepening primary account relationships and driving the strongest unit economics in our history. Our momentum gives us confidence to raise our outlook for the remainder of the year.”
Grindr Director George Raymond Zage III Sells $6.43M of Stock
George Raymond Zage III, Director, sold 500,000 shares of Grindr Inc. at $12.78 to $13.03 a share (average $12.87) in 2 transactions, worth $6.43M in total between Nov 2, 2026 and Nov 3, 2026. Shares held after the trade: 6,127,743 (-2.7%).
Western Union reported third quarter 2026 results with GAAP revenue of $1.0 billion, a 2% decrease year-over-year. The company saw 8% growth in Branded Digital revenue and transaction growth of 21%, while overall earnings were impacted by a slowdown in the North America retail business and expenses related to its efficiency program.
Term
Q3 2026
“As we move through the second half of the year, we continue to make progress against our Beyond strategy. Importantly, the initiatives we launched in the second quarter are streamlining our cost structure and have begun to materialize in our financial results. At the same time, we continue to invest in growth, including expanding our digital capabilities, embedding AI across key operational processes, and advancing our stablecoin and next-generation money movement initiatives. We are beginning to see the impact of all of these efforts and remain confident in our ability to improve performance and create long-term shareholder value.”
Devin McGranahan, President and Chief Executive Officer
Blue Owl Capital Corporation reported Q3 2026 net investment income of $0.34 per share and an increased NAV per share of $14.32. The company declared a total dividend of $0.32 per share for the quarter and noted strong credit quality with no new non-accruals.
Term
Q3 2026
“We are very pleased with OBDC's results this quarter, resulting in a 10.3% annualized return on net income. Earnings continued to comfortably cover the base dividend and NAV increased 40 basis points. Our borrowers have sustained year-over-year growth and credit quality remained strong, with no new issuers added to non-accrual”
Craig W. Packer, Chief Executive Officer
“Looking ahead, we are well positioned to benefit from improved market economics as investments originated at wider spreads begin to fund, while higher base rates could provide an additional tailwind as our floating-rate loans reset.”
Blue Owl Technology Finance Corp. reported Q3 2026 financial results with GAAP net investment income of $0.34 per share and a net asset value of $14.32 per share. The company declared a total dividend of $0.32 per share for the quarter and repurchased $35 million of common stock. Management noted strong credit quality and a 10.3% annualized return on net income.
Term
Q3 2026
“We are very pleased with OBDC's results this quarter, resulting in a 10.3% annualized return on net income. Earnings continued to comfortably cover the base dividend and NAV increased 40 basis points. Our borrowers have sustained year-over-year growth and credit quality remained strong, with no new issuers added to non-accrual.”
Craig W. Packer, Chief Executive Officer
“Looking ahead, we are well positioned to benefit from improved market economics as investments originated at wider spreads begin to fund, while higher base rates could provide an additional tailwind as our floating-rate loans reset.”
Mineralys Therapeutics reported Q3 2026 financial results and provided a corporate update regarding its lead candidate, lorundrostat, which has a PDUFA target date of December 22, 2026. The company also announced the resignation of board member Derek DiRocco, Ph.D., effective December 31, 2026.
“With approximately 20 million adults in the U.S. living with uncontrolled or resistant hypertension, despite treatment, there is a significant need for new treatment options. As we approach the December 22nd PDUFA target date for lorundrostat, our focus is on completing our launch preparations so that we are ready to reach patients quickly, pending approval.”
Jon Congleton, Chief Executive Officer of Mineralys
“We continue to receive positive feedback from providers, payers and people living with hypertension, and we look forward to the potential to bring lorundrostat to millions of patients in need.”
Jon Congleton, Chief Executive Officer of Mineralys
Kailera Therapeutics reported Q3 2026 financial results, ending the period with $847.4 million in cash and equivalents to support operations into mid-2028. The company highlighted significant clinical progress, including the full enrollment of its KaiNETIC Phase 3 program for injectable ribupatide and plans to initiate a Phase 3 program for oral ribupatide in 1H 2027.
Term
Q3 2026
“Kailera was built to bring new medicines to people living with obesity, and our strong execution this quarter reflects that commitment. All four of our product candidates are on track to deliver important clinical milestones in 2027, including the initiation of our Phase 3 trial for ribupatide oral and the data readout from the ribupatide injection high-dose Phase 2b trial. With the ribupatide franchise’s category-leading potential at the core of a diversified portfolio, and a balance sheet that supports multiple value-creating inflection points into mid-2028, I am proud of our team and energized by what we aim to deliver for people living with obesity.”
Ron Renaud, President and Chief Executive Officer of Kailera
CNB Financial Corp reported net interest income of $226.0 million for the nine months ended September 30, 2026, a significant increase from $167.8 million in the prior year period. Total assets remained stable at approximately $8.4 billion, while the company saw growth in its loan portfolio and wealth management fees.
Design Therapeutics reported third quarter 2026 financial results, posting a net loss of $20.3 million. The company ended the period with $208.6 million in cash and securities, which it expects will provide a strong financial runway for its clinical-stage GeneTAC programs. Key upcoming milestones include a registrational plan update for DT-216P2 in Q4 2026 and 12-week clinical data in Q1 2027.
“We remain focused on evaluating DT-216P2 over longer treatment durations and preparing for the next stage of clinical development in Friedreich ataxia. In DM1, our Phase 1 trial of DT-818 is evaluating an approach designed to selectively reduce transcription of the mutant DMPK allele, targeting the source of toxic RNA. Clinical readouts expected in 2027 will help guide these programs as we pursue our vision for the GeneTAC® platform: to address the underlying causes of serious genetic diseases and deliver meaningful benefits for patients.”
Pratik Shah, Ph.D., chairperson and chief executive officer of Design Therapeutics
Vaxcyte reported third quarter 2026 financial results and provided a business update, highlighting positive topline Phase 3 data for its VAX-31 adult pneumococcal vaccine candidate. The company strengthened its balance sheet with $1.1 billion in net proceeds from October equity and debt offerings, resulting in a pro forma cash position of approximately $3.4 billion. Vaxcyte remains on track for a planned BLA submission for VAX-31 in the first half of 2028.
Term
Q3 2026
“The positive topline results from OPUS-1 represent a significant milestone for Vaxcyte and our broad-spectrum pneumococcal conjugate vaccine (PCV) franchise. VAX-31 met all prespecified primary endpoints in this pivotal Phase 3 trial, which inaugurated a more stringent noninferiority standard, and we believe the results further support its potential best-in-class profile.”
Grant Pickering, Chief Executive Officer and Co-Founder of Vaxcyte
“Following our positive OPUS-1 results, we completed concurrent equity and convertible senior notes offerings, raising approximately $1.1 billion in net proceeds, to further strengthen our balance sheet and extend our cash runway. With approximately $3.4 billion in pro forma cash, cash equivalents and investments as of September 30, 2026, we are well positioned to support the potential U.S. commercial launch of VAX-31 for adults and advance our other key initiatives.”
Andrew Guggenhime, President and Chief Financial Officer of Vaxcyte
Remitly Global, Inc. reported significant growth for the nine months ended September 30, 2026, with revenue increasing to $1.46 billion from $1.19 billion in the prior year. The company achieved a substantial net income of $322.5 million, largely bolstered by a $136.0 million income tax benefit, compared to $26.7 million in the same period of 2025.
Root, Inc. reported total assets of $1.67 billion as of September 30, 2026, with a cash and cash equivalents balance of $596.3 million. The company maintains a dual-class stock structure with 13.4 million Class A and 1.8 million Class B shares outstanding as of late October 2026. Management's forward-looking statements emphasize a focus on embedded insurance partnerships, telematics data efficiency, and achieving long-term profitability.
agilon health, inc. reported a significant financial turnaround for the nine months ended September 30, 2026, achieving a net income of $101.8 million compared to a net loss of $202.5 million in the prior year period. This improvement was driven by a reduction in medical services expenses and a $19.0 million gain from discontinued operations.
Haverty Furniture Companies reported a net income of $6.3 million for the third quarter of 2026, an increase from $4.7 million in the prior year period. Net sales grew to $203.2 million, driven by improved gross margins and operational efficiencies despite higher selling, general, and administrative expenses.
KKR FS Income Trust $350M Debt Financing with Sumitomo Mitsui Banking Corporation
KKR FS Income Trust's subsidiary, K-FIT Finance SM-1 LLC, entered into a $350 million Loan and Servicing Agreement with Sumitomo Mitsui Banking Corporation as administrative agent. The facility allows for borrowings in multiple currencies and can be increased to a maximum of $1 billion, with a maturity date set for October 29, 2031.
Pegasystems Insider Dianne Ledingham Sells $34K of Stock
Dianne Ledingham sold 1,000 shares of Pegasystems Inc at $34.03 a share, worth $34K in total on Nov 2, 2026. Shares held after the trade: 37,280 (-2.6%).
Scott R. Lovett, Fastly's President of Go to Market, notified the company of his planned retirement in 2027. He will continue in his current role to support the transition and search for a new Chief Revenue Officer, followed by a period as a non-employee Senior Advisor through at least June 30, 2027. The company entered into a transition and separation agreement providing for continued base salary, commission eligibility, and equity vesting during the transition and consulting periods.
Fastly reported record third-quarter revenue of $190.2 million, representing 20% year-over-year growth, driven by strong adoption of security and network services. The company achieved record gross margins and generated positive free cash flow of $25.2 million. CEO Kip Compton highlighted the results as a reflection of customers deepening their use of the platform for AI scale and critical business outcomes.
Term
Q3 2026
“Our record third quarter results reflect strong execution as customers continued to adopt more of our products and deepen their use of our platform. Delivering record revenue and free cash flow demonstrates our value proposition as we help customers achieve critical business outcomes and build for AI scale.”
Veracyte reported Q3 2026 financial results with total revenue growing 15% year-over-year to $151.8 million, driven by strong performance in its Afirma and Decipher Prostate tests. The company also announced that its Board of Directors authorized a new $100 million share repurchase program to be executed over a one-year period.
“We delivered solid third quarter results supported by strong profitability and cash generation. Afirma outperformed, while Decipher Prostate volume was below our expectations. We remain confident in the long-term outlook of our business and expect a number of evidence-based catalysts to support growth in our core franchises while also advancing our breast and bladder strategies. As we execute on these opportunities, our differentiated financial profile enables us to continue investing in the business to drive long-term growth.”
Regeneron Pharmaceuticals Insider Christine A. Poon Sells $7.59M of Stock
Christine A. Poon sold 7,830 shares of Regeneron Pharmaceuticals, Inc. at $966.74 to $971.31 a share (average $969.09) in 6 transactions, worth $7.59M in total on Nov 2, 2026. Shares held after the trade: 5,219 (-3.7%).
Rapid7 reported third quarter 2026 financial results with total revenue of $212.4 million, a 2.5% year-over-year decrease. The company achieved GAAP net income of $3.5 million and non-GAAP net income of $47.4 million, while maintaining an annualized recurring revenue (ARR) of $819.7 million.
Term
Q3 2026
“Last quarter, we took decisive action to focus resources and energy on our core business. This quarter, we delivered on some of our early goals in this multi-quarter journey. The company is operating with greater discipline, our core business is becoming more stable, and our cash generation outlook for the year remains on track. That is real progress, but one quarter of stability is just a start. Turning this execution into durable growth is the work ahead of us.”
Wael Mohamed, CEO of Rapid7
“Discipline creates capacity, and strategy decides where it goes. We are putting that capacity behind our core and an AI-first service model where our platform, Rapid7 Intelligence, AI agents, and experienced security experts work as one system, taking customers beyond detection and response to resolution.”
Figma reported Q3 2026 revenue of $391.4 million, up 43% year-over-year, driven by strong seat expansion and AI credit consumption. The company achieved a non-GAAP operating income of $47.0 million and raised its full-year outlook based on momentum in AI-powered design tools and cost efficiencies.
Term
Q3 2026
“As code becomes a commodity, value is moving up the stack to design—and our Q3 results reflect that. We're building the full-stack canvas for visual-first development: one that's built for collaboration, increasingly powered by our first-party model and native to the way teams design and build with AI. This is Figma's opportunity and what we believe will fuel our next phase of growth.”
Dylan Field, Figma’s CEO and co-founder
“Q3 revenue grew 43% year-over-year, coming in well ahead of our prior guidance as customers continued to expand seats and invest more deeply in Figma. We’re seeing customers move from trying AI to making larger commitments, and the Figma agent is expanding how they use credits across our platform. That momentum, alongside improvements in AI cost efficiency, gives us confidence to raise our full-year revenue and non-GAAP operating income outlook while continuing to invest in our AI capabilities.”
Nuvation Bio Inc. reported financial results for the third quarter of 2026, highlighting continued progress in its clinical oncology programs. The company maintained a robust cash position to support operations through 2028, while reporting a net loss driven by ongoing research and development expenses.
AppLovin reported record Q3 2026 financial results with revenue growing 55% year-over-year to $2.18 billion and net income increasing 72% to $1.44 billion. The company also announced that its board of directors approved a $3.2 billion increase to its share repurchase authorization, bringing the total current capacity to $3.6 billion.